Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × trastuzumab deruxtecan × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 13 Neoplasm Metastasis 9 Stomach Neoplasms 5 Brain Neoplasms 4 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Salivary Gland Neoplasms 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Adenocarcinoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Testicular Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Osteosarcoma 1 Neoplasms 1 Mouth Neoplasms 1 Meningeal Carcinomatosis 1 Melanoma 1

Interventions

pembrolizumab 2 fludarabine 2 blinatumomab 2 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 relugolix 1 nilotinib 1 isatuximab 1 inavolisib 1 giredestrant 1 fludarabine phosphate 1 enzalutamide 1 abemaciclib 1 Transplantation 1 Monatide (IMS 3015) 1 Melphalan 1 Lenalidomide 1 Immunotherapy 1 Imatinib Mesylate 1 HMPL-013 1 Docetaxel 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Capecitabine 1 Calcium Dobesilate 1 Biological Assay 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡